This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Information on how to access Mylotarg™​​​​​​​​​​​​​​▼ (gemtuzumab ozogamicin) and cytarabine prescribing information and adverse event reporting can be found at the bottom of the page.

Efficacy

Median Event Free Survival* was significantly longer with MYLOTARG + chemotherapy vs chemotherapy alone1

ALFA-0701 study

Figure adapted from MYLOTARG Summary of Product Characteristics

* Defined as the time from randomisation to the date of assessment of the response (if CR or CRp had not been achieved), relapse or death.

CHEMO, chemotherapy; CI, confidence interval; CR, complete remission; CRp, complete remission with incomplete platelet recovery; EFS, event-free survival; HR, hazard ratios; mo, months; MYLO, MYLOTARG

EFS significantly improved with MYLOTARG in patients with intermediate and favourable cytogenetics vs chemotherapy

EFS in favourable/intermediate cytogenetics​​​​​​​1,2

The significant reduction in risk of EFS events is durable; 40% of patients in the MYLOTARG + chemotherapy arm are still alive in first remission at 3 years

EFS in Adverse cytogenetics​​​​​​​1,2

No statistically significant benefit seen for MYLOTARG in adverse cytogenetics population​​​​​​​

CHEMO, chemotherapy; CI, confidence interval; CR, complete remission; CRp, complete remission with incomplete platelet recovery; EFS, event-free survival; HR, hazard rarios; mo, months; MYLO, MYLOTARG

Explore more

Efficacy and Safety of MYLOTARG video


Watch Professor Robert Hills discuss the key clinical data from the pivotal ALFA study

Learn more

AML Landscape: Present and Future video


Watch Dr Eleni Tholouli discuss the NICE approval for MYLOTARG and efficacy data using the ALFA schedule

Learn more
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for how to report adverse reactions.
References
  1. MYLOTARG Summary of Marketing Product Characteristics.
  2. Pfizer Ltd. Data on File. CSR. 2018
PP-MYL-GBR-0225. March 2021

Read the Fast Facts Guide for brand overview

Click here to download a copy

Order a hard copy

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google Play or Apple App Store

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No